BCM
GOSS icon

Beaumont Capital Management’s Gossamer Bio GOSS Stock Holding History

Beaumont Capital Management’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-276
Closed -$3.64K – 39
2026
Q2 		$3.64K Buy
276
+141
+104% +$3.15K ﹤0.01% 34
2026
Q1 		$3.54K Buy
+135
New +$17K ﹤0.01% 32

Other funds holding GOSS

Context Capital Management
Context Capital Management Lajolla, California $4.89B AUM 1.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57.1B AUM 43.46% 1-Year Est. Return
Clearstead Advisors
Clearstead Advisors Cleveland, Ohio $10.8B AUM 17.88% 1-Year Est. Return

Beaumont Capital Management's GOSS Position: Q3 2026 in Review

Beaumont Capital Management sold out of Gossamer Bio (GOSS) in Q3 2026, closing a stake of 276 shares — an estimated $3.64K sold.

Beaumont Capital Management first reported a position in GOSS in Q1 2026 and held it in 2 quarters. The position peaked at $3.64K in Q2 2026. 19 funds tracked by Wall St. Rank hold GOSS as of Q3 2026.

  • Beaumont Capital Management reported no remaining Gossamer Bio position as of Q3 2026 after selling out during the quarter.
  • Beaumont Capital Management sold 276 Gossamer Bio shares in Q3 2026, an estimated $3.64K.
  • Beaumont Capital Management first reported a position in Gossamer Bio in Q1 2026 and held it in 2 quarters.
  • Beaumont Capital Management's Gossamer Bio position peaked at $3.64K in Q2 2026.
  • 19 funds tracked by Wall St. Rank held Gossamer Bio as of Q3 2026.

Based on Beaumont Capital Management's 13F filing for Q3 2026, filed 4 Nov 2026.